Top

Published in:

01-04-2005 | Article

Hypothyroidism in rats decreases peripheral glucose utilisation, a defect partially corrected by central leptin infusion

Authors: P. Cettour-Rose, C. Theander-Carrillo, C. Asensio, M. Klein, T. J. Visser, A. G. Burger, C. A. Meier, F. Rohner-Jeanrenaud

Published in: Diabetologia | Issue 4/2005

Abstract

Aims/hypothesis

The aims of this work were to determine the effect of hypothyroidism on insulin-stimulated glucose turnover and to unravel the potential mechanisms involved in such an effect.

Methods

Hypothyroidism was induced by administration of propylthiouracil, with partial T4 substitution. Euglycaemic–hyperinsulinaemic clamps, associated with the labelled 2-deoxy-d-glucose technique for measuring tissue-specific glucose utilisation, were used. To assess a possible involvement of leptin in the modulation of glucose metabolism by hypothyroidism, leptin was infused intracerebroventricularly for 6 days. A group of leptin-infused rats was treated with rT3 to determine a potential role of T3 in mediating the leptin effects.

Results

Compared with euthyroid rats, hypothyroid animals exhibited decreased overall glucose turnover and decreased glucose utilisation indices in skeletal muscle and adipose tissue. Leptinaemia in hypothyroid rats was lower while resistin mRNA expression in adipose tissue was higher than in euthyroid animals. Intracerebroventricular leptin infusion in hypothyroid rats partially restored overall, muscle and adipose tissue insulin-stimulated glucose utilisation and improved the reduced glycaemic response observed during insulin tolerance tests. The leptin effects were due neither to the observed increase in plasma T3 levels nor to changes in the high adipose tissue resistin expression of hypothyroid rats. The administration of leptin to hypothyroid animals was accompanied by increased expression of muscle and adipose tissue carnitine palmitoyl transferases, decreased plasma NEFA levels and reduced muscle triglyceride content.

Conclusions/interpretation

Hypothyroidism is characterised by decreased insulin responsiveness, partly mediated by an exaggerated glucose–fatty acid cycle that is partly alleviated by intracerebroventricular leptin administration.

Tata JR, Ernster L, Lindberg O (1962) Control of basal metabolic rate by thyroid hormones and cellular function. Nature 193:1058–1060

Silva JE (2003) The thermogenic effect of thyroid hormone and its clinical implications. Ann Intern Med 139:205–213

Oppenheimer JH, Schwartz HL, Lane JT et al (1991) Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. J Clin Invest 87:125–132

Weinstein SP, O’Boyle E, Haber RS (1994) Thyroid hormone increases basal and insulin-stimulated glucose transport in skeletal muscle. The role of GLUT4 glucose transporter expression. Diabetes 43:1185–1189

Dimitriadis G, Parry-Billings M, Bevan S et al (1997) The effects of insulin on transport and metabolism of glucose in skeletal muscle from hyperthyroid and hypothyroid rats. Eur J Clin Invest 27:475–483CrossRef

Weinstein SP, Watts J, Haber RS (1991) Thyroid hormone increases muscle/fat glucose transporter gene expression in rat skeletal muscle. Endocrinology 129:455–464

Dimitriadis GD, Leighton B, Parry-Billings M et al (1989) Effects of hypothyroidism on the sensitivity of glycolysis and glycogen synthesis to insulin in the soleus muscle of the rat. Biochem J 257:369–373

Arner P, Bolinder J, Wennlund A et al (1984) Influence of thyroid hormone level on insulin action in human adipose tissue. Diabetes 33:369–375

Andreani D, Menzinger G, Fallucca F et al (1970) Insulin levels in thyrotoxicosis and primary myxoedema: response to intravenous glucose and glucagon. Diabetologia 6:1–7CrossRef

10.

Ahren B (1986) Hyperthyroidism and glucose intolerance. Acta Med Scand 220:5–14

11.

Achmadi J, Terashima Y (1995) The effect of propylthiouracil-induced low thyroid function on secretion response and action of insulin in sheep. Domest Anim Endocrinol 12:157–166CrossRef

12.

van Dijk G (2001) The role of leptin in the regulation of energy balance and adiposity. J Neuroendocrinol 13:913–921CrossRef

13.

Ceddia RB, Koistinen HA, Zierath JR et al (2002) Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J 16:1163–1176CrossRefPubMed

14.

Valcavi R, Zini M, Peino R et al (1997) Influence of thyroid status on serum immunoreactive leptin levels. J Clin Endocrinol Metab 82:1632–1634CrossRef

15.

Yoshida T, Momotani N, Hayashi M et al (1998) Serum leptin concentrations in patients with thyroid disorders. Clin Endocrinol (Oxf) 48:299–302CrossRef

16.

Iglesias P, Alvarez Fidalgo P, Codoceo R et al (2003) Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. Clin Endocrinol (Oxf) 59:621–629CrossRef

17.

Leonhardt U, Ritzel U, Schafer G et al (1998) Serum leptin levels in hypo- and hyperthyroidism. J Endocrinol 157:75–79CrossRef

18.

Pinkney JH, Goodrick SJ, Katz J et al (1998) Leptin and the pituitary–thyroid axis: a comparative study in lean, obese, hypothyroid and hyperthyroid subjects. Clin Endocrinol (Oxf) 49:583–588CrossRef

19.

Chen MD, Song YM, Tsou CT et al (2000) Leptin concentration and the Zn/Cu ratio in plasma in women with thyroid disorder. Biol Trace Elem Res 75:99–105CrossRef

20.

Sesmilo G, Casamitjana R, Halperin I et al (1998) Role of thyroid hormones on serum leptin levels. Eur J Endocrinol 139:428–430CrossRef

21.

Miyakawa M, Tsushima T, Murakami H et al (1999) Serum leptin levels and bioelectrical impedance assessment of body composition in patients with Graves’ disease and hypothyroidism. Endocr J 46:665–673

22.

Ahima RS, Prabakaran D, Mantzoros C et al (1996) Role of leptin in the neuroendocrine response to fasting. Nature 382:250–252CrossRefPubMed

23.

Legradi G, Emerson CH, Ahima RS et al (1997) Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. Endocrinology 138:2569–2576CrossRef

24.

Seoane LM, Carro E, Tovar S et al (2000) Regulation of in vivo TSH secretion by leptin. Regul Pept 92:25–29CrossRef

25.

Cusin I, Rouru J, Visser T et al (2000) Involvement of thyroid hormones in the effect of intracerebroventricular leptin infusion on uncoupling protein-3 expression in rat muscle. Diabetes 49:1101–1105

26.

Flier JS, Harris M, Hollenberg AN (2000) Leptin, nutrition, and the thyroid: the why, the wherefore, and the wiring. J Clin Invest 105:859–861

27.

Cettour-Rose P, Burger AG, Meier CA et al (2002) Central stimulatory effect of leptin on T3 production is mediated by brown adipose tissue type II deiodinase. Am J Physiol Endocrinol Metab 283:E980–E987

28.

Rouru J, Cusin I, Zakrzewska KE et al (1999) Effects of intravenously infused leptin on insulin sensitivity and on the expression of uncoupling proteins in brown adipose tissue. Endocrinology 140:3688–3692CrossRef

29.

Cusin I, Zakrzewska KE, Boss O et al (1998) Chronic central leptin infusion enhances insulin-stimulated glucose metabolism and favors the expression of uncoupling proteins. Diabetes 47:1014–1019

30.

Rohner-Jeanrenaud F, Walker CD, Greco-Perotto R et al (1989) Central corticotropin-releasing factor administration prevents the excessive body weight gain of genetically obese (fa/fa) rats. Endocrinology 124:733–739

31.

Visser TJ (1996) Pathways of thyroid hormone metabolism. Acta Med Austriaca 23:10–16

32.

Silva JE, Leonard JL (1985) Regulation of rat cerebrocortical and adenohypophyseal type II 5′-deiodinase by thyroxine, triiodothyronine, and reverse triiodothyronine. Endocrinology 116:1627–1635

33.

Kaiser CA, Goumaz MO, Burger AG (1986) In vivo inhibition of the 5′-deiodinase type II in brain cortex and pituitary by reverse triiodothyronine. Endocrinology 119:762–770

34.

Cusin I, Terrettaz J, Rohner-Jeanrenaud F et al (1990) Metabolic consequences of hyperinsulinaemia imposed on normal rats on glucose handling by white adipose tissue, muscles and liver. Biochem J 267:99–103

35.

Vettor R, Zarjevski N, Cusin I et al (1994) Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats. Diabetologia 37:1202–1208

36.

Terrettaz J, Assimacopoulos-Jeannet F, Jeanrenaud B (1986) Severe hepatic and peripheral insulin resistance as evidenced by euglycemic clamps in genetically obese fa/fa rats. Endocrinology 118:674–678

37.

Kraegen EW, Clark PW, Jenkins AB et al (1991) Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 40:1397–1403

38.

Herbert V, Lau KS, Gottlieb CW et al (1965) Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25:1375–1384PubMed

39.

Geffner DL, Azukizawa M, Hershman JM (1975) Propylthiouracil blocks extrathyroidal conversion of thyroxine to triiodothyronine and augments thyrotropin secretion in man. J Clin Invest 55:224–229

40.

Saberi M, Sterling FH, Utiger RD (1975) Reduction in extrathyroidal triiodothyronine production by propylthiouracil in man. J Clin Invest 55:218–223

41.

Karakoc A, Ayvaz G, Taneri F et al (2004) The effects of hypothyroidism in rats on serum leptin concentrations and leptin mRNA levels in adipose tissue and relationship with body fat composition. Endocr Res 30:247–255CrossRef

42.

Shimomura I, Hammer RE, Richardson JA et al (1998) Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 12:3182–3194

43.

Ebihara K, Ogawa Y, Masuzaki H et al (2001) Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 50:1440–1448

44.

Haque WA, Shimomura I, Matsuzawa Y et al (2002) Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 87:2395CrossRef

45.

Steppan CM, Bailey ST, Bhat S et al (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312CrossRefPubMed

46.

Moon B, Kwan JJ, Duddy N et al (2003) Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation. Am J Physiol Endocrinol Metab 285:E106–E115

47.

Rajala MW, Obici S, Scherer PE et al (2003) Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 111:225–230CrossRefPubMed

48.

Pravenec M, Kazdova L, Landa V et al (2003) Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat. J Biol Chem 278:45209–45215

49.

Nogueiras R, Gualillo O, Caminos JE et al (2003) Regulation of resistin by gonadal, thyroid hormone, and nutritional status. Obes Res 11:408–414

50.

Shimomura I, Hammer RE, Ikemoto S et al (1999) Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73–76

51.

Oral EA, Simha V, Ruiz E et al (2002) Leptin-replacement therapy for lipodystrophy. N Engl J Med 346:570–578CrossRef

52.

Petersen KF, Oral EA, Dufour S et al (2002) Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 109:1345–1350CrossRefPubMed

53.

Farooqi IS, Jebb SA, Langmack G et al (1999) Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341:879–884CrossRefPubMed

54.

Hidaka S, Yoshimatsu H, Kondou S et al (2002) Chronic central leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin-induced diabetic rats. FASEB J 16:509–518CrossRef

55.

Randle PJ, Garland PB, Newsholme EA et al (1965) The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann N Y Acad Sci 131:324–333

56.

Asensio C, Cettour-Rose P, Theander-Carrillo C et al (2004) Changes in glycemia by leptin administration or high-fat feeding in rodent models of obesity/type 2 diabetes suggest a link between resistin expression and control of glucose homeostasis. Endocrinology 145:2206–2213CrossRef

Title: Hypothyroidism in rats decreases peripheral glucose utilisation, a defect partially corrected by central leptin infusion
Authors: P. Cettour-Rose
C. Theander-Carrillo
C. Asensio
M. Klein
T. J. Visser
A. G. Burger
C. A. Meier
F. Rohner-Jeanrenaud
Publication date: 01-04-2005
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 4/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-005-1696-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 4/2005

The metabolic actions of thyroid hormone and leptin: a mandatory interplay or not?

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

Prevalence and progression of impaired glucose homeostasis assessed by the different criteria for IFG in Japanese adults

Gene expression profiling of diabetic and galactosaemic cataractous rat lens by microarray analysis

A novel functional polymorphism (−336A/G) in the promoter of the partitioning-defective protein-6α gene is associated with increased glucose tolerance and lower concentrations of serum non-esterified fatty acids

Reduced whole-body lipid oxidation is associated with insulin resistance, but not with intramyocellular lipid content in offspring of type 2 diabetic patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials